​

Ultragenyx Pharmaceutical (RARE) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

RARE Stock Forecast

Ultragenyx Pharmaceutical (RARE) stock forecast, based on 32 Wall Street analysts, predicts a 12-month average price target of $89.75, with a high of $115.00 and a low of $64.00. This represents a 151.47% increase from the last price of $35.69.

$35 $51 $67 $83 $99 $115 High: $115 Avg: $89.75 Low: $64 Last Closed Price: $35.69

RARE Stock Rating

Ultragenyx Pharmaceutical stock's rating consensus is Buy, based on 32 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 27 Buy (84.38%), 4 Hold (12.50%), 1 Sell (3.12%), and 0 Strong Sell (0.00%).

Buy
Total 32 1 4 27 Strong Sell Sell Hold Buy Strong Buy

RARE Price Target Upside V Benchmarks

TypeNameUpside
StockUltragenyx Pharmaceutical151.47%
SectorHealthcare Stocks 35.94%
IndustryBiotech Stocks 83.61%

Price Target Trends

1M3M12M
# Anlaysts-29
Avg Price Target-$89.50$96.78
Last Closing Price$35.69$35.69$35.69
Upside/Downside-150.77%171.17%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 257111--19
Mar, 257111--19
Feb, 257121--20
Jan, 257131--21
Dec, 247131--21
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 17, 2025Piper Sandler$115.00$39.64190.11%222.22%
Mar 07, 2025Morgan Stanley$64.00$38.6265.72%79.32%
Nov 06, 2024Ed ArceH.C. Wainwright$95.00$51.2085.55%166.18%
Nov 06, 2024Joseph SchwartzLeerink Partners$85.00$51.2066.02%138.16%
Jun 06, 2024Salveen RichterGoldman Sachs$67.00$41.4561.64%87.73%
May 31, 2024Dae Gon HaStifel Nicolaus$127.00$38.65228.59%255.84%
May 31, 2024Christopher RaymondRaymond James$135.00$38.65249.29%278.26%
May 31, 2024Joel BeattyRobert W. Baird$72.00$38.6586.29%101.74%
May 31, 2024Whitney IjemCanaccord Genuity$111.00$38.65187.19%211.01%
Apr 15, 2024Dae Gon HaStifel Nicolaus$124.00$42.87189.25%247.44%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 21, 2024Wells FargoBuyBuyhold
Oct 01, 2024Cowen & Co.BuyBuyhold
Sep 20, 2024Wells FargoBuyBuyhold
Aug 02, 2024WedbushNeutralNeutralhold
Aug 02, 2024Cantor FitzgeraldOverweightOverweighthold
Jul 22, 2024WedbushBuyBuyhold
Jun 17, 2024Cowen & Co.BuyBuyhold
May 31, 2024BarclaysOverweightOverweighthold
May 31, 2024WedbushBuyBuyhold
May 31, 2024Cantor FitzgeraldOverweightOverweighthold

Financial Forecast

EPS Forecast

$-15 $-9 $-3 $3 $9 $15 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.07$-6.70$-10.12$-8.25$-6.29----
Avg Forecast$-3.79$-6.25$-9.92$-8.37$-6.21$-5.11$-3.40$-0.17$4.13
High Forecast$-3.62$-5.97$-8.61$-7.92$-5.92$-3.82$-0.80$10.08$4.20
Low Forecast$-4.26$-7.03$-10.84$-9.13$-6.64$-6.32$-5.82$-9.87$4.02
Surprise %-19.00%7.20%2.02%-1.43%1.29%----

Revenue Forecast

$0 $400M $800M $1B $2B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$271.03M$351.41M$363.33M$434.25M$560.23M----
Avg Forecast$250.02M$351.78M$361.74M$428.63M$546.66M$645.00M$858.55M$1.22B$1.83B
High Forecast$273.74M$385.16M$387.56M$432.53M$556.16M$647.02M$870.71M$1.28B$1.85B
Low Forecast$241.23M$339.42M$325.03M$423.24M$536.88M$643.00M$846.38M$1.17B$1.79B
Surprise %8.40%-0.11%0.44%1.31%2.48%----

Net Income Forecast

$-1B $-600M $-200M $200M $600M $1B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-186.57M$-454.02M$-707.42M$-606.64M$-569.18M----
Avg Forecast$-176.32M$-396.60M$-413.87M$-606.64M$-461.94M$-372.86M$-338.45M$13.07M$303.83M
High Forecast$-120.40M$-317.28M$-331.09M$-485.31M$-435.51M$-281.15M$-58.80M$741.13M$309.09M
Low Forecast$-232.24M$-475.92M$-496.64M$-727.97M$-488.37M$-464.57M$-427.75M$-725.65M$295.72M
Surprise %5.81%14.48%70.93%-23.22%----

RARE Forecast FAQ

Is Ultragenyx Pharmaceutical stock a buy?

Ultragenyx Pharmaceutical stock has a consensus rating of Buy, based on 32 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 27 Buy, 4 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Ultragenyx Pharmaceutical is a favorable investment for most analysts.

What is Ultragenyx Pharmaceutical's price target?

Ultragenyx Pharmaceutical's price target, set by 32 Wall Street analysts, averages $89.75 over the next 12 months. The price target range spans from $64 at the low end to $115 at the high end, suggesting a potential 151.47% change from the previous closing price of $35.69.

How does Ultragenyx Pharmaceutical stock forecast compare to its benchmarks?

Ultragenyx Pharmaceutical's stock forecast shows a 151.47% upside, outperforming the average forecast for the healthcare stocks sector (35.94%) and outperforming the biotech stocks industry (83.61%).

What is the breakdown of analyst ratings for Ultragenyx Pharmaceutical over the past three months?

  • April 2025: 36.84% Strong Buy, 57.89% Buy, 5.26% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 36.84% Strong Buy, 57.89% Buy, 5.26% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 35.00% Strong Buy, 60.00% Buy, 5.00% Hold, 0% Sell, 0% Strong Sell.

What is Ultragenyx Pharmaceutical’s EPS forecast?

Ultragenyx Pharmaceutical's average annual EPS forecast for its fiscal year ending in December 2025 is $-5.11, marking a -18.76% decrease from the reported $-6.29 in 2024. Estimates for the following years are $-3.4 in 2026, $-0.17 in 2027, and $4.13 in 2028.

What is Ultragenyx Pharmaceutical’s revenue forecast?

Ultragenyx Pharmaceutical's average annual revenue forecast for its fiscal year ending in December 2025 is $645M, reflecting a 15.13% increase from the reported $560.23M in 2024. The forecast for 2026 is $858.55M, followed by $1.22B for 2027, and $1.83B for 2028.

What is Ultragenyx Pharmaceutical’s net income forecast?

Ultragenyx Pharmaceutical's net income forecast for the fiscal year ending in December 2025 stands at $-373M, representing a -34.49% decrease from the reported $-569M in 2024. Projections indicate $-338M in 2026, $13.07M in 2027, and $303.83M in 2028.